In this episode of MD Newsline, Dr. Neelam Vashi, board-certified dermatologist at the Dermatology Institute of Boston, provides a comprehensive overview of psoriasis as a chronic immune-mediated systemic condition. She discusses how our understanding of psoriasis has evolved beyond a "skin disease" to a disorder with important systemic implications, including joint disease and cardiometabolic risk.

Dr. Vashi shares practical insights into diagnosis, screening for comorbidities, treatment selection across disease severities, and the rapidly advancing biologic landscape. She also addresses common misconceptions, adherence challenges, and the psychosocial impact of psoriasis.

Episode Highlights: Understanding Psoriasis as a Systemic Disease

Psoriasis is a chronic immune-driven condition that leads to thickened, inflamed skin—but its impact goes far beyond the surface. Dr. Vashi explains the importance of recognizing systemic inflammation, including joint involvement and cardiovascular risk.

Screening for Psoriatic Arthritis

Early identification of joint symptoms is critical. Dr. Vashi outlines simple screening questions clinicians can use in busy practices and emphasizes timely rheumatology referral to prevent permanent joint damage.

Cardiometabolic Risk and Lifestyle Counseling

Psoriasis is associated with increased cardiovascular risk due to systemic inflammation. Dr. Vashi discusses the importance of blood pressure monitoring, smoking cessation, weight management, and heart-healthy lifestyles.

Genetics and Environmental Triggers

Both genetic predisposition and environmental factors—such as infections, stress, and immune triggers—play roles in disease onset and flares. Adult-onset psoriasis is common, even in patients without childhood history.

Treatment Decision-Making: Topicals to Systemics

Treatment is individualized based on disease severity, body surface area, location, and quality-of-life impact. Dr. Vashi reviews when to use:

· Topical therapies (corticosteroids, vitamin D analogs)

· Phototherapy

· Oral small molecules (PDE4 and TYK2 inhibitors)

· Biologic therapies (TNF-alpha, IL-17, IL-23 inhibitors)

The Biologic Era: Clear to Almost Clear Skin

Modern targeted biologics have transformed moderate-to-severe psoriasis care, making clear or nearly clear skin an achievable goal for many patients.

Managing Special Populations

Treatment strategies may shift in pregnancy, pediatrics, older adults, and patients with liver, kidney, or inflammatory bowel disease. Shared decision-making remains central.

Difficult-to-Treat Areas

Scalp, nails, palms, soles, genital, and inverse psoriasis require tailored approaches and careful formulation selection to minimize irritation and maximize adherence.

Addressing Treatment Fatigue and Adherence

With psoriasis being chronic, long-term management is key. Extended dosing intervals and maintenance strategies help reduce treatment fatigue.

Common Misconceptions

Dr. Vashi dispels myths that psoriasis is contagious, caused by poor hygiene, or triggered directly by specific foods. Education remains essential for both patients and families.

Post-Inflammatory Pigment Changes

After inflammation resolves, patients may experience hyperpigmentation, hypopigmentation, or erythema—particularly in individuals with darker skin tones. Early aggressive treatment may reduce pigmentary changes.

Key Takeaway

Psoriasis is a systemic inflammatory condition that requires comprehensive, patient-centered care. With modern therapies—including highly targeted biologics—clinicians can achieve clear or nearly clear skin while also addressing joint disease, cardiometabolic risk, and quality-of-life concerns. Early intervention, shared decision-making, and ongoing monitoring are critical to optimizing long-term outcomes.

Resources:

Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/

Contact with Dr. Neelam Vashi: Here